Active Ingredient History

  • Now
Ezogabine (U.S. adopted name) or retigabine (international nonproprietary name) is one of a family of aminopyrroles with anticonvulsant activity. It is used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was approved by the European Medicines Agency under the trade name Trobalt and by the United States Food and Drug Administration (FDA), under the trade name Potiga. The mechanism by which ezogabine exerts its therapeutic effects has not been fully elucidated. In vitro studies indicate that ezogabine enhances transmembrane potassium currents mediated by the KCNQ (Kv7.2 to 7.5) family of ion channels. By activating KCNQ channels, ezogabine is thought to stabilize the resting membrane potential and reduce brain excitability. This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including migraine, tinnitus and neuropathic pain. In vitro studies suggest that ezogabine may also exert therapeutic effects through augmentation of GABA-mediated currents.   NCATS

  • Mol. Mass: 303.3314
  • ALogP: 3.59
  • ChEMBL Molecule:
More Chemistry
awd-21360 | d 20443 | d-20443 | d 23129 | d-23129 | ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate | ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate | ethyl n-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride | ezg | ezogabine | gke-841 | gw582892x | gw 582892x | ke 841 | n-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester | n-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester | potiga | retigabine | rtg | trobalt | way 143841 | way-143841


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue